文献速递血液净化与透析慢性肾脏病

透析肾衰竭患者的抗凝治疗:凝血因子XI作为治疗靶点

Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target.
PubMed 文献 · Kidney Int · 2021-09-30

全球约10%人口患慢性肾脏病,透析肾衰竭患者心血管事件风险最高,但缺乏降低该风险的证据。长期抗凝可能预防血栓栓塞但研究不足,现有数据限于维生素K拮抗剂或直接口服抗凝药(抑制凝血酶或FXa),出血风险是主要顾虑。FXI在血栓形成中作用大于止血,可能成为更安全的抗凝靶点。本文阐述肾衰竭患者抗凝治疗的理由、现有抗凝药的局限性、FXI抑制剂的潜在益处及正在进行的相关研究。

要点

  • 透析肾衰竭患者心血管事件风险最高,但支持降低该风险的疗法证据匮乏。
  • 现有抗凝药(维生素K拮抗剂或直接口服抗凝药)出血风险是主要顾虑。
  • FXI在血栓形成中作用大于止血,可能成为更安全的抗凝靶点。

核心结论

  • FXI抑制剂可能为透析肾衰竭患者提供更安全的抗凝选择,但需进一步研究验证。

研究设计与样本

  • 本文为综述,未报告系统检索范围或样本量。

主要发现

  • 慢性肾脏病全球患病率约10%,与超额死亡和发病相关。
  • 肾小球滤过率降低和蛋白尿是心血管疾病的强独立危险因素。
  • 透析肾衰竭患者心血管事件(如卒中或心肌梗死)风险最高。
  • 现有抗凝数据限于维生素K拮抗剂或直接口服抗凝药,出血风险是主要顾虑。
  • FXI在血栓形成中作用大于止血,是潜在更安全的抗凝靶点。

临床怎么用

  • 透析肾衰竭患者心血管风险高,但现有抗凝治疗证据不足且出血风险突出。
  • FXI抑制剂作为潜在更安全抗凝策略,需等待正在进行的相关研究结果。

局限性

  • 支持肾衰竭患者抗凝治疗的证据匮乏,现有数据有限。
  • 关于FXI抑制剂在透析患者中的疗效和安全性尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic kidney disease is present in almost 10% of the world population and is associated with excess mortality and morbidity. Reduced glomerular filtration rate and the presence and extent of proteinuria, key domains of chronic kidney disease, have both been shown to be strong and independent risk factors for cardiovascular disease. Patients with kidney failure requiring dialysis are at highest risk for cardiovascular events (e.g., stroke or myocardial infarction), and of developing chronic cardiovascular conditions, such as heart failure. Despite the high burden of cardiovascular disease, there is a paucity of evidence supporting therapies to reduce this risk. Although long-term anticoagulant treatment has the potential to prevent thromboembolism in persons with kidney failure on dialysis, this possibility remains understudied. The limited data available on anticoagulation in patients with kidney failure has focused on vitamin K antagonists or direct oral anticoagulants that inhibit thrombin or factor (F) Xa. The risk of bleeding is a major concern with these agents. However, FXI is emerging as a potential safer target for new anticoagulants because FXI plays a greater part in thrombosis than in hemostasis. In this article, we (i) explain the rationale for considering anticoagulation therapy in patients with kidney failure to reduce atherothrombotic events, (ii) highlight the limitations of current anticoagulants in this patient population, (iii) explain the potential benefits of FXI inhibitors, and (iv) summarize ongoing studies investigating FXI inhibition in patients with kidney failure on dialysis.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Eikelboom J, Floege J, Thadhani R, et al. Anticoagulation in patients with kidney failure on dialysis: factor XI as a therapeutic target. Kidney Int. 2021. PMID: 34600964. doi:10.1016/j.kint.2021.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。